ACADIA Pharmaceuticals Inc. (ACAD)
ACAD Stock Price Chart
Explore ACADIA Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze ACAD price movements and trends.
ACAD Company Profile
Discover essential business fundamentals and corporate details for ACADIA Pharmaceuticals Inc. (ACAD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 May 2004
Employees
653.00
Website
https://www.acadia-pharm.comCEO
Catherine E. Owen Adams
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Financial Timeline
Browse a chronological timeline of ACADIA Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.14, while revenue estimate is $276.52M.
Earnings released on 6 Aug 2025
EPS came in at $0.16 surpassing the estimated $0.14 by +14.29%, while revenue for the quarter reached $264.57M , beating expectations by +0.98%.
Earnings released on 7 May 2025
EPS came in at $0.11 surpassing the estimated $0.10 by +10.00%, while revenue for the quarter reached $244.32M , beating expectations by +2.24%.
Earnings released on 26 Feb 2025
EPS came in at $0.17 surpassing the estimated $0.13 by +30.77%, while revenue for the quarter reached $259.60M , missing expectations by -4.92%.
Earnings released on 6 Nov 2024
EPS came in at $0.20 surpassing the estimated $0.14 by +42.86%, while revenue for the quarter reached $250.40M , missing expectations by -11.49%.
Earnings released on 6 Aug 2024
EPS came in at $0.20 surpassing the estimated $0.18 by +11.11%, while revenue for the quarter reached $241.96M , beating expectations by +2.78%.
Earnings released on 8 May 2024
EPS came in at $0.10 surpassing the estimated $0.05 by +100.00%, while revenue for the quarter reached $205.83M , missing expectations by -1.18%.
Earnings released on 27 Feb 2024
EPS came in at $0.28 falling short of the estimated $0.30 by -6.67%, while revenue for the quarter reached $231.04M , beating expectations by +3.24%.
Earnings released on 2 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.43 by +6.98%, while revenue for the quarter reached $211.70M , missing expectations by -5.65%.
Earnings released on 2 Aug 2023
EPS came in at $0.01 surpassing the estimated -$0.12 by +108.33%, while revenue for the quarter reached $165.24M , beating expectations by +4.68%.
Earnings released on 8 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%, while revenue for the quarter reached $118.46M , missing expectations by -1.35%.
Earnings released on 27 Feb 2023
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $136.49M , beating expectations by +1.68%.
Earnings released on 2 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached $130.71M , missing expectations by -5.80%.
Earnings released on 8 Aug 2022
EPS came in at -$0.21 surpassing the estimated -$0.25 by +16.00%, while revenue for the quarter reached $134.56M , beating expectations by +3.19%.
Earnings released on 4 May 2022
EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%, while revenue for the quarter reached $115.47M , missing expectations by -5.29%.
Earnings released on 28 Feb 2022
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%, while revenue for the quarter reached $130.76M , missing expectations by -3.42%.
Earnings released on 8 Nov 2021
EPS came in at -$0.09 surpassing the estimated -$0.27 by +66.67%, while revenue for the quarter reached $131.61M , missing expectations by -2.78%.
Earnings released on 4 Aug 2021
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%, while revenue for the quarter reached $115.22M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.42 surpassing the estimated -$0.53 by +20.75%, while revenue for the quarter reached $106.55M , missing expectations by -3.33%.
Earnings released on 24 Feb 2021
EPS came in at -$0.42 surpassing the estimated -$0.48 by +12.50%, while revenue for the quarter reached $121.01M , missing expectations by -1.83%.
Earnings released on 4 Nov 2020
EPS came in at -$0.54 falling short of the estimated -$0.38 by -42.11%, while revenue for the quarter reached $120.58M , beating expectations by +42.11%.
ACAD Stock Performance
Access detailed ACAD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.